Resum
Triple-negative breast cancer (TNBC) is a subclass of breast cancer and a heterogeneous disease that includes basal-like and claudin-low tumors. Claudin-low tumors are enriched for features associated with epithelial-to-mesenchymal transition (EMT) [1] and possibly for tumor initiating cells [2,3]. Some authors prefer the classification of ‘triple-negative-basal-like’ and ‘triple-negative-non-basal’. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide, accounting for 23% (1.38 million) of total new cancer cases and 14% (458,400) of total cancer deaths in 2008 [4]. Approximately 15–30% of women with breast cancer have TNBC [2,3].
Idioma original | Anglès |
---|---|
Títol de la publicació | Molecular-Based Decision Making for Personalized Cancer Management |
Lloc de publicació | London |
Editor | Future Medicine Ltd. |
Pàgines | 75-88 |
Nombre de pàgines | 14 |
ISBN (electrònic) | 9781780841533 |
ISBN (imprès) | 9781780841557 |
DOIs | |
Estat de la publicació | Publicada - de set. 2012 |